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Abstract 
The pharmaceutical industry is currently dominated by the traditionally implemented, yet wasteful and 
inefficient, batch production paradigm. Continuous Pharmaceutical Manufacturing (CPM) shows 
potential to bring technological innovation, cost savings and environmental benefits to pharmaceutical 
firms. This paper describes the process modelling and simulation of CPM of two active pharmaceutical 
ingredient (API) cases: diphenhydramine (a globally-marketed antishistamine) and artemisinin (an 
important antimalarial drug), with focus on implementing a continuous separation process for each. The 
continuous liquid-liquid extraction of diphenhydramine and crystallisation of artemisinin are compared to 
the batch methods, in order to demonstrate the benefits of material efficiency and economic viability of 
continuous separations in pharmaceutical manufacturing.  
1. Introduction 
Batch manufacturing methods have historically dominated the pharmaceutical industry, with benefits of 
versatile equipment usage, specific batch recall, long residence times for exploring different reaction 
pathways (1), and well-established regulatory protocol (2). However, batch manufacturing necessitates 
large equipment, intensive labour (3), limited automation and frequent plant reconfiguration (4). 
Additionally, costs associated with R&D and bringing new drug products to market have drastically 
increased over previous decades (5). Increasing competition from generics manufacturers also poses a 
significant threat to pharmaceutical firm profitability. Technological innovation is required to ensure 
sustainability for pharmaceutical enterprises (6). 
Continuous Pharmaceutical Manufacturing (CPM) is a new production paradigm receiving attention 
from the highest regulatory levels due to its potential for reduced costs, lower material input and waste 
handling and reduced footprints (7). CPM offers enhanced mixing and heat transfer efficiencies, safer 
operation under hazardous conditions and improved yields (8). However, CPM is yet to be widely 
adopted due to significant investments in batch infrastructures (2) and legislative constraints (9). 
Furthermore, challenges in scaleup and solids handling are critical issues to be addressed (10). To 
facilitate the transition from batch manufacturing, CPM benefits must be conclusively illustrated for 
active substances of societal importance and high global demand (11). 
Pharmaceutical manufacturing is one of the most wasteful industrial sectors, producing 200 times 
more waste than petroleum manufacturing (12). Approximately 56% of this waste is attributed to solvent 
usage (13). Separations in upstream pharmaceutical manufacturing is particularly wasteful due to strict 
product purity requirements (14). To elucidate CPM waste reduction and economic benefits, continuous 
separation process alternatives must be investigated. 
Candidate separation process screening via process modelling and simulation is critical prior to 
financial investments in experimentation and scaleup (15-16) as detailed in recent studies (11, 17-18). 
This work demonstrates the benefits of continuous separations by examining two API case studies: 
diphenhydramine, a popular antihistamine, and artemisinin (17), an important antimalarial drug. 
Theoretical modelling of conceptual continuous separations illustrates the importance of conducting 
technoeconomic analyses in the early stages of design to identify promising candidate CPM processes. 
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2. Green Continuous Flow Syntheses and Separations  
To demonstrate the feasibility and viability of continuous separations in pharmaceutical manufacturing, 
promising unit operations must be investigated for integration into fully continuous CPM flowsheets. 
Continuous flow syntheses of a wide range of APIs and the development of continuous downstream 
processes is documented in the literature (19-23). Here, we present and discuss the steady-state 
process modelling results of the CPM for two APIs, diphenhydramine (this work) and artemisinin (17), 
whose conceptual continuous separations show improvements over the batch methods. API recoveries 
and material efficiencies are compared for batch and continuous separation options. In both cases, a 
plant capacity of 100 kg API per annum and 8000 h of annual operation are assumed. Figure 1 shows 
conceptual flowsheets and demonstrated reaction pathways for the CPM of both APIs. Both APIs are 
produced in flow using plug flow reactors (PFRs), in accordance with experimental studies (24). 
 
 
Figure 1: Conceptual flowsheets for continuous production of A. Diphenhydramine, adapted from Snead and 
Jamison, 2013 (25), B. Artemisinin (17), adapted from Kopetzki et al., 2013 (26). 
 
 
2.1 Diphenhydramine  
Diphenhydramine is most commonly used as a first-generation antihistamine and is globally marketed 
in various brand formulations (Benadryl®, Unisom®, Tylenol®, Zzzquil®). The continuous flow synthesis 
of diphenhydramine (25) features a single-step synthesis at 180 °C (Figure 1) between 
chlorodiphenylmethane (CDPM) and dimethylaminoethanol (DMAE) in carrier solvent, N-
methylpyrrolidone (NMP). The demonstrated batch separation of diphenhydramine employs a three-
stage liquid-liquid extraction (LLE) with diethyl ether, attaining an API recovery of 80% (25). We 
compare a single-stage continuous LLE separation (Figure 2) to the batch separation. Cyclohexane 
(CyHex) and methylcyclohexane (MeCyHex) are compared as continuous LLE solvents, considering an 
operating temperature of 20 °C and a solvent-to-feed ratio (S:F, mass basis) of 5. 
Modelling of continuous LLE of diphenhydramine requires estimation of the composition of each 
liquid phase in the process and of the API solubility in each phase. Liquid-liquid and solid-liquid 
equilibria are estimated via the UNIFAC and NRTL models. The partition coefficient of API between 
liquid phases is assumed to equal the ratio of API solubilities in each phase. 
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Figure 2: Continuous separation: A. Diphenhydramine (liquid-liquid extraction), B. Artemisinin (crystallisation) (17). 
 
 
2.2 Artemisinin  
Artemisinin is traditionally produced by extensive batch cultivation and extraction (27). A recently 
demonstrated continuous flow synthesis of the API uses dihydroartemisinic acid (DHAA), a waste 
component of the currently implemented batch separation, as a feedstock (26, 28). Toluene is the 
carrier solvent for the process (Figure 1). The demonstrated batch separation comprises 17 stages 
(including neutralisation, evaporation, drying, washes, crystallisations and filtrations) to obtain the API at 
70.1% yield (26). Here, we consider continuous antisolvent crystallisation of artemisinin (similar to 
recent efforts for artemisinin crystallisation (29)), comparing ethyl acetate (EtOAc) and acetonitrile 
(ACN) as candidate antisolvents (Figure 2). S:F ratios of 2.33 and 4 are considered for EtOAc and 
ACN, respectively. In both cases, the feed to the continuous crystalliser is considered at 90% API 
saturation in the toluene-antisolvent mixture at 40 °C, and the target mother liquor composition is the 
API saturation concentration of the mixture at 5 °C. A flash evaporation for solvent removal is required 
to meet the required feed composition. The API recovery is calculated as the thermodynamically 
possible crystallisation yield from these respective conditions. 
 
3. Attainable Recoveries and Material Efficiencies  
API recoveries and material efficiencies for batch and continuous separations are compared. Material 
efficiences are quantified by the environmental (E)-factor, the mass ratio of waste-to-product, and the 
mass productivity (MP), quantifying how efficiently material is used (12). Continuous separations are 
modelled as single-stage ideal processes. Efficiencies versus thermodynamic equilibrium (80, 90 and 
100%) are considered to account for continuous stage inefficiencies. 
 
3.1 API Recoveries  
The continuous LLE of diphenhydramine attains API recoveries of 70.6−88.3% for CyHex and 
64.9−81.1% for MeCyHex (Figure 3). Improved recoveries relative to the batch separation (25) are only 
attainable when 100% efficiency versus thermodynamic equilibria is assumed. This highlights the 
importance of considering stage efficiencies of continuous separation processes.  
For the continuous crystallisation of artemisinin from the toluene-antisolvent mixture, EtOAc attains 
higher API recoveries (45.8−57.2%) than ACN (42.1−52.6%) as shown in Figure 3. The batch 
separation system attains an API recovery of 70.1% due to its extensive nature (26). EtOAc is the most 
promising antisolvent for CPM, attaining a higher API recovery compared to ACN (Table 1). A broader 
antisolvent consideration must also include safety, ecotoxicity and life cycle assessment (31). Process 
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Analytical Technology (PAT), high-fidelity instrumentation and (preferably model-based) automatic 
control strategies (28) are essential to ensure the intended continuity of the process, and the 
minimisation of inevitable start-up and shut-down times. 
 
 
Figure 3: Comparison of performances of continuous separation schemes vs. batch separation methods (17). 
 
 
3.2 Material Efficiencies: E-Factors and Mass Productivities  
The continuous LLE of diphenhydramine incurs poorer material efficiencies (higher E-factors, lower 
MPs) than the batch separation for both LLE solvents (Table 1) due to the large volumes of LLE solvent 
required to attain comparable API recoveries. Nevertheless, computed E-factors and MPs are still 
acceptably low for pharmaceutical processes (30). 
The continuous crystallisation of artemisinin is significantly more efficient is terms of material usage 
than the batch separation (26), as shown in Table 1. This is due to the greater number of unit 
operations and material requirements for the batch separation (26) compared to our conceptual 
continuous separation process (17-18).  
 
Table 1: Environmental (E)-factors and mass productivities (MPs). 
DIPHENHYDRAMINE 
 
ARTEMISININ 
 
 
Batch 
 
Efficiency vs. 
Thermodynamic 
Equilibria  
(%) 
Continuous  
Liquid-Liquid Extraction (LLE)  
 
Batch Efficiency vs. 
Thermodynamic 
Equilibria  
(%) 
Continuous 
Crystallisation 
CyHex MeCyHex 
 
EtOAc ACN 
E (—) 10.2 
  80 34.3 39.0 
 
E (—) 65.3 
  80 21.8 27.7 
  90 30.3 34.5   90 19.3 24.6 
100 27.2 31.1 100 17.4 22.1 
MP (%)   8.9 
  80   2.8   2.5 
 
MP (%)   1.5 
  80   4.4   3.5 
  90   3.2   2.8 
 
  90   4.9   3.9 
100   3.5   3.1 
 
100   5.4   4.3 
 
4. Economic Benefits of Continuous Separations 
Demonstrating the cost savings benefits available via CPM is imperative in order to make a convincing 
business case. Our economic analysis compares the cost benefits available by implementing 
continuous separations. Capital (CapEx) and operating (OpEx) expenditures and total costs (adjusted 
for inflation) for a 20-year lifetime and a 5% discount rate have been calculated. The designed CPM 
plants are considered at an existing pharmaceutical manufacturing site, with essential auxiliary 
infrastructure available. Plant throughputs and unit size modelling consider reported reaction and 
projected separation efficiencies to meet the required plant capacity. Calculation of CapEx, OpEx and 
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total costs follow the methodology of a published CPM economic analysis (32). CapEx comprises 
battery limits installed costs and working capital and construction. OpEx comprises materials, utilities 
and waste handling requirements. Equipment and material prices are quoted from various vendors. 
Equipment costs have been scaled for varying unit size and year of purchase. Cost savings of 
continuous separation options relative to the batch separations are shown in Figure 4. 
 
 
Figure 4: A comparative illustration of CapEx, OpEx and Total Cost of continuous separations (18). 
 
 
Continuous LLE of diphenhydramine allows significant CapEx savings: 28.5−36.3% savings are 
available using CyHex, and 25.6−34.0% savings are available using MeCyHex (Figure 4). Such cost 
savings are attainable due to the reduced equipment dimensions via CPM (33). Using CyHex leads to 
47.6−84.5% increase in OpEx due to the large solvent quantity (S:F = 5) required to meet the calculated 
API recovery and the high price of CyHex. Meanwhile, OpEx savings of 35.2−48.1% using MeCyHex 
are available, due to the lower material price compared to CyHex. The total costs savings benefits of 
implementing MeCyHex (27.9−37.4%) are significantly greater than for CyHex (1.7−16.4%). MeCyHex 
is the best candidate LLE solvent for CPM of diphenhydramine based upon the economics presented. 
For the continuous crystallisation of artemisinin, CapEx savings of 6.6−22.4% are available for 
EtOAc usage. A slight increase in CapEx (0.3%) is incurred when assuming 80% efficiency versus 
thermodynamic equilibrium for ACN usage; CapEx savings of 9.2% and 16.9% are attainable when 
considering 90% and 100% efficiencies versus thermodynamic equilibrium, respectively. Such savings 
are mainly due to the significant reduction in equipment requirements for the continuous separation in 
comparison to the 17-step batch route (26). OpEx savings of 4.4% and 22.5% are attainable using 
EtOAc (for 90 and 100% efficiencies versus thermodynamic equilibrium, respectively), whilst an OpEx 
increase of 7.3% is incurred for 80% efficiency versus thermodynamic equilibrium. ACN usage leads to 
an OpEx increase of 25.5−56.2%. This difference is due to the poorer API recovery and high S:F 
required for ACN compared to EtOAc. Total costs savings of 5.8−22.5% are attainable using EtOAc. 
For ACN, total costs savings of 6.5 % and 14.5% are attainable (for 90 and 100% efficiencies versus 
thermodynamic equilibrium, respectively), whilst an increase in total costs of 3.3% is incurred for 80% 
efficiency versus thermodynamic equilibrium. EtOAc usage allows greater total costs savings for all 
efficiencies considered; thus, its usage for continuous crystallisation of artemisinin is preferred. 
The present technoeconomic analysis of both CPM processes indicates that continuous separation 
allows for significant material efficiency and cost savings over batch separation methods. Process 
modelling for plantwide simulation and economic analysis employ essential assumptions, and the 
scaling up of CPM processes can induce cost saving variations, as we have already demonstrated (18). 
Life-Cycle Analysis (LCA) investigations of plant operation and capacity effects are thus encouraged.  
 
4. Conclusions 
Continuous Pharmaceutical Manufacturing (CPM) has been established as a promising alternative to 
the currently implemented batch methods in the pharmaceutical industry. Process modelling and 
simulation facilitates the screening of candidate unit operations for purification of active pharmaceutical 
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ingredients (APIs). The CPM case studies described here for two critical APIs, diphenhydramine and 
artemisinin (17), demonstrate the benefits of enhanced material efficiency and cost savings attainable 
via continuous separation and the importance of separation solvent selection. Systematic process 
modelling and simulation approaches facilitate the quantification of enhanced process performance and 
the design of efficient, cost-effective separations, towards meaningful transitions to continuous 
manufacturing in the pharmaceutical industry. 
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